Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GDP-fucose + 2-O-MeGal-beta-1,3GlcNAc
GDP + 2-O-MeGal-beta-1,3(Fuc-alpha-1,4)GlcNAc
17.6% activity
-
-
?
GDP-fucose + 2-O-MeGal-beta-1,4GlcNAc
GDP + 2-O-MeGal-beta-1,4(Fuc-alpha-1,3)GlcNAc
100% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo agalacto glycoprotein
GDP + ?
42.9% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo glycoprotein
GDP + ?
73.8% activity
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin
type 2 reaction
-
-
?
GDP-fucose + GalNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GalNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
91.9% activity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
GDP + ?
63.8% acivity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
GDP + ?
61.5% acivity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GlcNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
89.1% activity
-
-
?
Fucalpha(1-2)Galbeta(1-3)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Fucalpha(1-2)Galbeta(1-3)[Fucalpha(1-4)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
Fucalpha(1-2)Galbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Fucalpha(1-2)Galbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
Galbeta(1-3)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Galbeta(1-3)[Fucalpha(1-4)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
Galbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Galbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
GDP-beta-L-fucose + asialofetuin
GDP + ?
-
-
-
-
?
GDP-beta-L-fucose + beta-D-galactosyl-(1->3)-N-acetyl-D-glucosaminyl-R
GDP + beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-R
-
isoform Fut3 predominantly exhibits alpha1-4 fucosyltransferase activity
-
-
?
GDP-beta-L-fucose + beta-D-Galp-(1,3)-beta-D-GlcNAcp-O-(CH2)6-NH-dansyl
GDP + beta-D-Galp-(1,3)[alpha-L-Fuc-(1,4)]-beta-D-GlcNAcp-O-(CH2)6-NH-dansyl
-
-
-
-
?
GDP-beta-L-fucose + fetuin triantennary asialoglycopeptide
?
-
-
-
-
?
GDP-beta-L-fucose + Fucalpha(1->2)Galbeta(1->3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Fucalpha1,2Galbeta(1->4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta(1->3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta(1->4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha(2,6)Galbeta(1,4)GlcNAc
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha(2->3)Galbeta(1->3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha(2->3)Galbeta(1->4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha2-3Galbeta1-4Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
?
-
the enzyme catalyzes the fucose transfer from GDP-fucose to GlcNAc residues of the sialylated polylactosamine acceptor leading to two isomeric monofucosyl antigens, VIM2 and sialyl-Lex
-
-
?
GDP-beta-L-fucose + NeuAcalpha2-3Galbeta1-4Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
GDP + NeuAcalpha2-3Galbeta1-4[Fucalpha1-3]Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
-
the enzyme catalyzes the fucose transfer from GDP-fucose to GlcNAc residues of the sialylated polylactosamine acceptor leading to two isomeric monofucosyl antigens, VIM2 and sialyl-Lex
i.e. sialyl-Lex, main product of FucT-VI, i.e. VIM2, main product of FucT-V
-
?
GDP-beta-L-fucose labelled with ATTO 550 + N-acetyllactosamine labelled with ATTO 647N
?
-
-
-
-
?
GDP-D-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
?
-
-
-
-
?
GDP-fucose + 2-O-MeGal-beta-1,3GlcNAc
GDP + 2-O-MeGal-beta-1,3(Fuc-alpha-1,4)GlcNAc
19.4% activity
-
-
?
GDP-fucose + 2-O-MeGal-beta-1,4GlcNAc
GDP + 2-O-MeGal-beta-1,4(Fuc-alpha-1,3)GlcNAc
100% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo agalacto glycoprotein
GDP + ?
5.2% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo glycoprotein
GDP + ?
36.9% activity
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin
type 1 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin
type 2 reaction
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAc
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAc-beta-1,3Gal-beta-1,4Glc
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-beta-1,3Gal-beta-1,4Glc
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAc-O-(CH2)3NHCO(CH2)5NH-biotin
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-O-(CH2)3NHCO(CH2)5NH-biotin
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
GDP + Gal-beta-1,3[alpha-L-fucosyl-(1,4)]GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
-
-
-
?
GDP-fucose + Gal-beta-1,4-Glc
GDP + Gal-beta-1,4(Fuc-alpha-1,3)Glc
-
-
-
-
?
GDP-fucose + Gal-beta-1,4GlcNAc
GDP + Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc + Gal-beta-1,4(Fuc-alpha-1,2)GlcNAc
-
enzyme activity is divided into 66% alpha-1,3FucT and 34% alpha-1,2FucT
-
-
?
GDP-fucose + Gal-beta-1,4GlcNAc-beta-1-R
GDP + Gal-beta-1,4(fuc-alpha-1,3)GlcNAc-beta-1-R
-
-
-
-
?
GDP-fucose + GalNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GalNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
95.0% activity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
?
acivity not determined
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
?
acivity not determined
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GlcNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
11.3% activity
-
-
?
GDP-fucose + LacNAc
?
-
-
-
-
?
GDP-L-fucose + (Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
GDP + Fucalpha(1-3)(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
-
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
GDP-L-fucose + 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn
GDP + 2-O-MeGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn
-
-
-
-
?
GDP-L-fucose + 3-O-MeGalbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
GDP + 3-O-MeGalbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
-
16.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 17.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 3-O-sulfoGalbeta(1,3)GlcNAcbeta(1,3)Galbeta-O-Al
GDP + 3-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta-O-Al
-
64.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 82.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
GDP + 3-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Al
-
64.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 62.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 3-O-sulfoGalbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
GDP + 3-O-sulfoGalbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
-
10.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 14.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 6-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
GDP + 6-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Al
-
3.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + alpha(2,3)-sialyllactosamine
GDP + ?
-
56% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + ancrod
GDP + ?
-
-
-
-
?
GDP-L-fucose + asialo ancrod
GDP + ?
-
-
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
GDP-L-fucose + fetuin triantennary glycopeptide
GDP + ?
-
-
-
-
?
GDP-L-fucose + formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
GDP + ?
-
-
-
-
?
GDP-L-fucose + Fuc-alpha1-2Galbeta1-4GlcNAc-octyl
GDP + ?
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + ?
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-(CH2)5-NH-biotin
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)5-NH-biotin
-
193% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-R
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))Glc
-
34.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 38.7% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
3% of the activity with with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin, enzyme expressed in Sf9 cells
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-(CH2)5-NH-biotin
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)5-NH-biotin
-
9.3% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAc-R
GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAcbeta-O-Naph
GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Naph
-
42.6 of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 46.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,3)(6-O-sulfo)GlcNAcbeta(1,3)Galbeta-O-Al
GDP + ?
-
15.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 19.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
GDP-L-fucose + Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc-R
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
20% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAcbeta-O-Bn
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn
-
79.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 83.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)-(5-thioGlc)
GDP + ?
-
51% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
GDP-L-fucose + Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
2% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin, enzyme expressed in Sf9 cells
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
33% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(3-O-MeGalbeta(1,3))GalNAcalpha-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(3-O-MeGalbeta(1,3))GalNAcalpha-O-Bn
-
2.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(3-O-sulfoGalbeta(1,3))-GalNAcalpha-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(3-O-sulfoGalbeta(1,3))-GalNAcalpha-O-Bn
-
1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
-
2.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta-O-Bn
-
3.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 2.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbetaOallyl
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl
-
64% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,4)Glucal
GDP + Galbeta(1,4)(Fucalpha(1,3))Glucal
-
10% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,6)Galbeta(1,4)Glc
GDP + ?
-
-
-
-
?
GDP-L-fucose + Galbeta(1-3)GlcNAcbeta-O-Me
GDP + Fucalpha(1-3)Galbeta(1-3)GlcNAcbeta-O-Me
-
-
-
-
?
GDP-L-fucose + Galbeta1-4GlcNAc-4-nitrophenyl
GDP + ?
-
-
-
-
?
GDP-L-fucose + GalNAcbeta(1,3)(6-O-sulfo)GlcNAcbeta-O-Me
GDP + ?
-
6.2 of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 8.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + GalNAcbeta1-4GlcNAc-diaminopimelyl
GDP + ?
-
-
-
-
?
GDP-L-fucose + GalNAcbeta1-4GlcNAc-octyl
GDP + ?
-
shows the highest catalytic activity as an acceptor substrate
-
-
?
GDP-L-fucose + IL-4 receptor
GDP + ?
-
-
-
-
?
GDP-L-fucose + Lewis antigen
GDP + fucosylated Lewis antigen
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
GDP + N-[(1R,3R,5R,6S,7S,8R,13R,15R,16R,17S)-6,17-dihydroxy-5-hydroxymethyl-15-methoxy-7-((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl]-acetamide
-
low activity with FucT IV and FucT VI
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
GDP + N-[(1R,3R,5R,6S,7S,8R,13R,15R,16R,17S)-6,17-dihydroxy-5-hydroxymethyl-15-methoxy-7-((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl]-acetamide
-
-
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
GDP + ?
-
-
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
GDP + ?
-
-
-
-
?
GDP-L-fucose + N-acetyllactosamine
GDP + alpha-1,3-L-fucosyl-N-acetyllactosamine
-
-
-
-
?
GDP-L-fucose + NeuAc(2,3)Galbeta(1,4)Glucal
GDP + NeuAc(2,3)Galbeta(1,4)(Fucalpha(1,3))Glucal
-
330% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + NeuAc(2,6)Galbeta(1,4)GlcNAc
GDP + NeuAc(2,6)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
13% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAc-(CH2)5-NH-biotin
GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)5-NH-biotin
-
57% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn
GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn
-
55.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 64.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
620% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
-
24.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 12.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta-O-Bn
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta-O-Bn
-
6.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 7.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbetaOallyl
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl
-
380% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)AspNHCO-biotin + GDP
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
NeuAcalpha(2-3)Galbeta(1-3)[Fucalpha(1-4)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
NeuAcalpha(2-3)Galbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
pyridylamine-lacto-N-neotetraose + GDP-fucose
GDP + ?
-
-
-
-
?
additional information
?
-
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme catalyzes the synthesis of fucosylated Lewis motifs that are associated with cell-adhesion events and are differentially expressed during cell differentiation
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
-
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme has a clear preference for the Galbeta3GlcNAc motif in oligosaccharides conjugated with the hydrophobic tail (CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
-
-
-
-
?
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
-
254% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
-
11% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
-
-
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
-
no activity
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
-
the acceptor oligosaccharide in bovine asialofetuin is the man3 branched triantennary isomer with one Galbeta(1,3)GlcNAc
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
activity of the wild-type enzyme is about 3% of the activity with Fucalpha(1,2)Galbeta(1,4)GlcNAc. The mutation W111R shows higher activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc than for Fucalpha(1,2)Galbeta(1,4)GlcNAc. The addition mutation in W11R/D112E increases activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc compared to mutant W111R
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
i.e. lacto-N-fucopentaose I
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
mutant enzyme D336A shows 40fold reduction in activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
130% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
29% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
420% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
45.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 51% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
-
-
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
-
145% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
-
i.e. lactose, 2% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
i.e. N-acetyllactosamine
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
3.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
43% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
-
-
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
-
28% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Lewis antigen
GDP + fucosylated Lewis antigen
-
on the cell surface of hepatocarcinoma cells H7721
-
-
?
GDP-L-fucose + Lewis antigen
GDP + fucosylated Lewis antigen
-
the enzyme, especially subtype FucT VI, is responsible for alpha-1,3-fucosylation in the synthesis of Lewis antigens Lex, SLex, and SDLex on the cell surface consist of sialylated or nonsialylated N-acetyllactosamine located on the outer chains of the glycan moieties of glycolipids or the O-linked glycans of glycoproteins, the isozymes prefer sialylated, alphaFucT III, V, VI, and VII, or nonsialylated, alphaFucT IV and IX, N-acetyllactosamine
-
-
?
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
?
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
FUT10 activity toward the acceptor 0989-BM is increased by about 50% compared with those observed using BGA-biotin
-
-
?
additional information
?
-
the enzyme is involved in the biosynthesis of the E-selectin ligand, sialyl-Lewis X. Catalyzes the transfer of fucose from GDP-beta-fucose to alpha-2,3 sialylated substrates
-
-
?
additional information
?
-
-
the enzyme is involved in the biosynthesis of the E-selectin ligand, sialyl-Lewis X. Catalyzes the transfer of fucose from GDP-beta-fucose to alpha-2,3 sialylated substrates
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galbeta1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galbeta1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
-
11 nonidentical amino acids, found within a hypervariable peptide segment positioned at the NH2 terminus determins whether or not a alpha(1,3)-fucosyltransferase can utilize type I acceptor substrates to form Lewis a and sialyl Lewis a moieties
-
-
?
additional information
?
-
-
activity with type 2 substrates is 1% or less than the activity with type 1 substrates
-
-
?
additional information
?
-
-
high substrate affinity for clustered units of 3-sialyl Galbeta(1,3)GlcNAcbeta in asparagine linked carbohydrate as well as for mucin core 2 structure containing 3-sialyl Galbeta1,4GlcNAcbeta-unit, in addition of alpha(1,2)-L-fucosylating activity
-
-
?
additional information
?
-
-
the enzyme transferrs fucose to the O-4-position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides and glycoproteins containing the type I Galbeta(1,3)GlcNAc motif
-
-
?
additional information
?
-
-
the enzyme is involved in the biosynthesis of the sialyl Lewis x, i.e. Lex, epitope on leukocytes, which has been identified as an important component of leukocyte ligands for E- and P-selectin
-
-
?
additional information
?
-
-
no activity with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-beta-1,3Gal-beta-1,4Glc, Fuc-alpha-1,2Gal-beta-1,4Glc, and NeuAc-alpha-2,3-Gal-beta-1,4GlcNAc
-
-
?
additional information
?
-
-
substrate specificity of FucT IV and FucT VI with N-acetyllactosamine derivatives, determination of the required conformational properties of oligosaccharide acceptors
-
-
?
additional information
?
-
-
the strong correlation between the promoter activity of the FUT III gene and the high expression of sialyl Le(a) observed in different colon carcinoma cell lines seems to conform the important regulatory role of FUT3 in the synthesis of sialyl Le(a)
-
-
?
additional information
?
-
-
FucT-III and FucT-V catalyze fucose transfer to Galbeta1-3GlcNAc chain acceptors in an alpha1,4-linkage, these two enzymes have distinct site-specific fucosylation properties, site-specific fucosylation is defined within a 40-amino acid segment containing 8 amino acid differences between the two enzymes, FucT-VI has about 12fold higher activity compared with FucT-V with the Trp124/Arg110 site in the enzymes being responsible primarily for this activity difference, substrate specificities of wild-type and mutant enzymes, overview
-
-
?
additional information
?
-
-
FucT-III catalyzes the transfer of fucose onto position-4 or position-3 of the N-acetylglucosamine unit of disaccharides beta-D-Galp-(1,3)-beta-D-GlcpNAc or beta-D-Galp-(1,4)-beta-D-GlcpNAc, respectively. FucT-III is an inverting enzyme
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galb1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galb1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
-
FUT6 can synthesize sialyl Lewis x in KATO III cells whereas FUT5 is most likely responsible for the synthesis of this epitope in HT29 and MKN45 cells. FUT3 and to a lower extent FUT5 have the capability to synthesize sialyl Lewis a
-
-
?
additional information
?
-
-
the enzyme transfers fucose from the GDP-fucose donor onto different glycoconjugate acceptors, such as, glycoproteins, glycolipids and oligosaccharides. Isoforms FUT3 to FUT7 and FUT9 to FUT11 belong to the group of alpha1,3/4-fucosyltransferases. FUT3 predominantly exhibits alpha1,4-fucosyltransferase activity synthesizing Lewis a, NeuAcalpha2,3Galbeta(1->3)[Fucalpha(1->4)]GlcNAc-R and Lewis b, and a minor alpha1,3-FUT activity, synthesizing Lewis x, sialyl Lewis x and Lewis y. FUT5 and FUT6 synthesize Lewis x and NeuAcalpha2,3Galbeta(1->4)[Fucalpha(1->3)]GlcNAc-R. FUT7 is an alpha1,3-FUT that synthesizes only sialyl Lewis x. FUT4 and FUT9 produce Lewis x and Lewis y. FUT10 and FUt11 exhibit alpha1,3-fucosyltransferase activity
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3-galactosyl-n-acetylglucosaminide 4-alpha-l-fucosyltransferase deficiency
Synthesis of {alpha}(1,3) fucosyltransferases IV- and VII-dependent eosinophil selectin ligand and recruitment to the skin.
Adenoma
Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases.
Breast Neoplasms
Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes.
Breast Neoplasms
Fucosyltransferase IV (FUT4) as an effective biomarker for the diagnosis of breast cancer.
Breast Neoplasms
Gene expression of fucosyl- and sialyl-transferases which synthesize sialyl Lewisx, the carbohydrate ligands for E-selectin, in human breast cancer.
Breast Neoplasms
MicroRNA-106b targets FUT6 to promote cell migration, invasion, and proliferation in human breast cancer.
Breast Neoplasms
miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and ?1,3-fucosylated glycans.
Breast Neoplasms
Role of fucosyltransferase IV in epithelial-mesenchymal transition in breast cancer cells.
Breast Neoplasms
Specific detection of sialyl Lewis X determinant carried on the mucin GlcNAcbeta1-->6GalNAcalpha core structure as a tumor-associated antigen.
Breast Neoplasms
[Study on relationship of fucosyltransferase gene types in breast cancer with metastasis and prognosis]
Carcinoma
alpha-2,3-Sialyltransferase type 3N and alpha-1,3-fucosyltransferase type VII are related to sialyl Lewis(x) synthesis and patient survival from lung carcinoma.
Carcinoma
Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases.
Carcinoma
Altered mRNA expression of glycosyltransferases in human gastric carcinomas.
Carcinoma
C2-O-sLeX glycoproteins are E-selectin ligands that regulate invasion of human colon and hepatic carcinoma cells.
Carcinoma
Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines.
Carcinoma
Differential fucosyltransferase IV expression in squamous carcinoma cells is regulated by promoter methylation.
Carcinoma
Fucosyltransferase III and sialyl-Le(x) expression correlate in cultured colon carcinoma cells but not in colon carcinoma tissue.
Carcinoma
Metastatic potential of human CX-1 colon adenocarcinoma cells is dependent on the expression of sialosyl Le(a) antigen.
Carcinoma
Neutrophil interactions with sialyl lewis X on human nonsmall cell lung carcinoma cells regulate invasive behavior.
Carcinoma
Promoter analysis of the human alpha1,3/4-fucosyltransferase gene (FUT III).
Carcinoma
Role of sialosyl Lewis(a) in adhesion of colon cancer cells--the antisense RNA approach.
Carcinoma
Sialosyl-Le(x) expression defines invasive and metastatic properties of bladder carcinoma.
Carcinoma
Up-regulation of a set of glycosyltransferase genes in human colorectal cancer.
Carcinoma, Hepatocellular
Transcriptional regulation of the fucosyltransferase VI gene in hepatocellular carcinoma cells.
Carcinoma, Squamous Cell
Differential fucosyltransferase IV expression in squamous carcinoma cells is regulated by promoter methylation.
Carcinoma, Squamous Cell
Fucosyltransferase IV enhances expression of MMP-12 stimulated by EGF via the ERK1/2, p38 and NF-?B pathways in A431 cells.
Colonic Neoplasms
Altered mRNA expression of specific molecular species of fucosyl- and sialyl-transferases in human colorectal cancer tissues.
Colonic Neoplasms
Death receptor 5 is activated by fucosylation in colon cancer cells.
Colonic Neoplasms
The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach.
Colorectal Neoplasms
Alpha1,3 fucosyltransferase VII plays a role in colorectal carcinoma metastases by promoting the carbohydration of glycoprotein CD24.
Colorectal Neoplasms
Altered mRNA expression of specific molecular species of fucosyl- and sialyl-transferases in human colorectal cancer tissues.
Colorectal Neoplasms
Evidence that the aberrant alpha 1-->2fucosyltransferase found in colorectal carcinoma may be encoded by Fuc-TIII (Le) gene.
Colorectal Neoplasms
Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer.
Colorectal Neoplasms
The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach.
Colorectal Neoplasms
Up-regulation of a set of glycosyltransferase genes in human colorectal cancer.
Coronary Disease
Fucosyltransferase 3 polymorphism and atherothrombotic disease in the Framingham Offspring Study.
Eosinophilia
Synthesis of {alpha}(1,3) fucosyltransferases IV- and VII-dependent eosinophil selectin ligand and recruitment to the skin.
Esophageal Neoplasms
Upregulation of Fucosyltransferase 3, 8 and protein O-Fucosyltransferase 1, 2 genes in esophageal cancer stem-like cells (CSLCs).
Infections
Expression of a human alpha-1,3/4-fucosyltransferase in the pit cell lineage of FVB/N mouse stomach results in production of Leb-containing glycoconjugates: a potential transgenic mouse model for studying Helicobacter pylori infection.
Infections
Use of flow cytometry to monitor infection and recombinant human alpha-1,3/4 fucosyltransferase production in baculovirus infected Sf9 cell cultures.
Infections
Viral vector-mediated delivery of competing glycosyltransferases modifies epitope expression cell specifically.
Inflammatory Bowel Diseases
[Association of inflammatory bowel disease with the polymorphisms and haplotypes of fucosyltransferase 3 gene].
Leukemia
Expression of alpha-(1,3)-fucosyltransferases which synthesize sialyl Le(x) and sialyl Le(a), the carbohydrate ligands for E- and P-selectins,in human malignant cell lines.
Leukemia
Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes.
Leukemia
Transcriptional regulation of expression of carbohydrate ligands for cell adhesion molecules in the selectin family.
Leukemia, Erythroblastic, Acute
Expression of GDP-L-Fuc: Gal(beta 1-4)GlcNAc-R (Fuc to GlcNAc) alpha-1,3-fucosyltransferase and its relationship to glycoprotein structure in a human erythroleukemia cell line, HEL.
Leukemia, T-Cell
Human T-cell leukemia virus-1 encoded Tax protein transactivates alpha 1-->3 fucosyltransferase Fuc-T VII, which synthesizes sialyl Lewis X, a selectin ligand expressed on adult T-cell leukemia cells.
Leukemia, T-Cell
Transcriptional regulation of expression of carbohydrate ligands for cell adhesion molecules in the selectin family.
Leukemia-Lymphoma, Adult T-Cell
Human T-cell leukemia virus-1 encoded Tax protein transactivates alpha 1-->3 fucosyltransferase Fuc-T VII, which synthesizes sialyl Lewis X, a selectin ligand expressed on adult T-cell leukemia cells.
Leukemia-Lymphoma, Adult T-Cell
Suppression of sialyl Lewis X expression and E-selectin-mediated cell adhesion in cultured human lymphoid cells by transfection of antisense cDNA of an alpha1-->3 fucosyltransferase (Fuc-T VII).
Liver Neoplasms
The Expression of Human alpha(1,3) Fucosyltransferase in Human Liver Cancer by in situ Hybridization.
Lung Neoplasms
Expression of alpha-1,3-fucosyltransferase type IV and VII genes is related to poor prognosis in lung cancer.
Lung Neoplasms
FUT4siRNA augments the chemosensitivity of non-small cell lung cancer to cisplatin through activation of FOXO1-induced apoptosis.
Lung Neoplasms
Neutrophil interactions with sialyl lewis X on human nonsmall cell lung carcinoma cells regulate invasive behavior.
Melanoma
A sialyl-Le(x)-negative melanoma cell line binds to E-selectin but not to P-selectin.
Melanoma
Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes.
Melanoma
Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression.
Melanoma
Role of fucosyltransferase IV in the migration and invasion of human melanoma cells.
Neoplasm Metastasis
Alpha1,3 fucosyltransferase VII plays a role in colorectal carcinoma metastases by promoting the carbohydration of glycoprotein CD24.
Neoplasm Metastasis
Fucosyltransferase IV (FUT4) as an effective biomarker for the diagnosis of breast cancer.
Neoplasm Metastasis
Human fucosyltransferase 6 enables prostate cancer metastasis to bone.
Neoplasm Metastasis
Metastatic potential of human CX-1 colon adenocarcinoma cells is dependent on the expression of sialosyl Le(a) antigen.
Neoplasm Metastasis
miR-200b inhibits proliferation and metastasis of breast cancer by targeting fucosyltransferase IV and ?1,3-fucosylated glycans.
Neoplasm Metastasis
Role of fucosyltransferase IV in epithelial-mesenchymal transition in breast cancer cells.
Neoplasm Metastasis
Tumor-associated macrophages promote Ezrin phosphorylation-mediated epithelial-mesenchymal transition in lung adenocarcinoma through FUT4/LeY up-regulation.
Neoplasm Metastasis
[Study on relationship of fucosyltransferase gene types in breast cancer with metastasis and prognosis]
Neoplasms
alpha-2,3-Sialyltransferase type 3N and alpha-1,3-fucosyltransferase type VII are related to sialyl Lewis(x) synthesis and patient survival from lung carcinoma.
Neoplasms
Altered mRNA expression of glycosyltransferases in human colorectal carcinomas and liver metastases.
Neoplasms
Altered mRNA expression of specific molecular species of fucosyl- and sialyl-transferases in human colorectal cancer tissues.
Neoplasms
Cyclophosphamide-induced apoptosis in A431 cells is inhibited by fucosyltransferase IV.
Neoplasms
Differential fucosyltransferase IV expression in squamous carcinoma cells is regulated by promoter methylation.
Neoplasms
Expression of alpha-(1,3)-fucosyltransferases which synthesize sialyl Le(x) and sialyl Le(a), the carbohydrate ligands for E- and P-selectins,in human malignant cell lines.
Neoplasms
Fucosyltransferase IV enhances expression of MMP-12 stimulated by EGF via the ERK1/2, p38 and NF-?B pathways in A431 cells.
Neoplasms
FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.
Neoplasms
Gene expression of fucosyl- and sialyl-transferases which synthesize sialyl Lewisx, the carbohydrate ligands for E-selectin, in human breast cancer.
Neoplasms
Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4.
Neoplasms
Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-?B/p65 signaling pathway to promote melanoma cell death.
Neoplasms
Neutrophil interactions with sialyl lewis X on human nonsmall cell lung carcinoma cells regulate invasive behavior.
Neoplasms
Overexpression of fucosyltransferase IV in A431 cell line increases cell proliferation.
Neoplasms
Platelet-endothelial interactions in inflamed mesenteric venules.
Neoplasms
Role of fucosyltransferase IV in epithelial-mesenchymal transition in breast cancer cells.
Neoplasms
Sialosyl-Le(x) expression defines invasive and metastatic properties of bladder carcinoma.
Neoplasms
The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach.
Neoplasms
Tumor-associated macrophages promote Ezrin phosphorylation-mediated epithelial-mesenchymal transition in lung adenocarcinoma through FUT4/LeY up-regulation.
Osteosarcoma
Identification of Key Genes and miRNAs in Osteosarcoma Patients with Chemoresistance by Bioinformatics Analysis.
Pancreatic Diseases
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice.
Pancreatic Neoplasms
Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Polycystic Kidney Diseases
Family-based analysis identified CD2 as a susceptibility gene for primary open angle glaucoma in Chinese Han population.
Prostatic Neoplasms
Human fucosyltransferase 6 enables prostate cancer metastasis to bone.
Spondylitis, Ankylosing
Associations between fucosyltransferase 3 gene polymorphisms and ankylosing spondylitis: A case-control study of an east Chinese population.
Squamous Cell Carcinoma of Head and Neck
Human Ly-6 antigen E48 (Ly-6D) regulates important interaction parameters between endothelial cells and head-and-neck squamous carcinoma cells.
Tuberculosis
Fucosyltransferase IV and VII-directed selectin ligand function determines long-term survival in experimental tuberculosis.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.12 - 2.7
(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
0.16 - 0.4
2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn
0.047 - 0.1
3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
0.045
ancrod
-
enzyme form FTB
-
0.167
asialo ancrod
-
enzyme form FTB
-
0.63
fetuin triantennary asialoglycopeptide
-
enzyme form FTB
-
1.43
fetuin triantennary glycopeptide
-
enzyme form FTB
-
0.075 - 1.3
Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
0.2 - 2.5
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.1 - 1.3
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.14
Fuc-alpha1-2Galbeta1-4GlcNAc-octyl
-
-
0.1 - 3.8
Fucalpha(1,2)Galbeta(1,3)GlcNAc
0.8
Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
1.52
Fucalpha(1,2)Galbeta(1,4)Glc
-
enzyme form FTB
0.5 - 0.7
Fucalpha(1,2)Galbeta(1,4)GlcNAc
0.7 - 3.3
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
0.6 - 12.7
Galbeta(1,3)GlcNAc
0.76 - 0.87
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
2.4
Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
0.012
Galbeta(1,4)(5-thioGlc)
-
-
0.035 - 8.1
Galbeta(1,4)GlcNAc
0.4
Galbeta(1,4)GlcNAcbeta(1,2)Man
-
-
3.8
Galbeta(1,4)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
0.016
Galbeta(1,4)GlcNAcbetaOallyl
-
-
0.034
Galbeta(1,4)Glucal
-
-
12
Galbeta(1,6)Galbeta(1,4)Glc
-
-
0.35 - 1.2
Galbeta(1-3)GlcNAcbeta-O-Me
3.6
Galbeta1-4GlcNAc-4-nitrophenyl
-
-
3.8
GalNAcbeta1-4GlcNAc-diaminopimelyl
-
-
0.27
GalNAcbeta1-4GlcNAc-octyl
-
-
0.1145
GDP-D-fucose
-
mutant enzyme D336A
0.005 - 0.035
GDP-L-fucose
0.15 - 0.154
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin
3 - 25
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
1.1 - 11
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
0.61 - 16
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
0.4 - 5
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
0.67 - 2.5
NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn
0.1 - 0.28
NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
0.77 - 3.3
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
0.064
NeuAcalpha(2,3)Galbeta(1,4)Glucal
-
-
0.07
NeuAcalpha(2,6)Galbeta(1,4)GlcNAc
-
-
0.12
(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
pH 6.5, 37°C, recombinant FucT VI
2.7
(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
pH 6.5, 37°C, recombinant FucT IV
0.16
2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn
-
enzyme form FTB
0.4
2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn
-
enzyme form FTA
0.047
3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
-
enzyme form FTB
0.1
3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
-
enzyme form FTA
0.075
Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
-
pH 6.5, 37°C, recombinant FucT VI
1.3
Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
-
pH 6.5, 37°C, recombinant FucT IV
0.2
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
wildtype
0.3
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
mutant W111F
0.3
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
mutant W111Y
2.5
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
mutant W111A
0.1
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
mutant W124R
1.1
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
wildtype
1.3
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
mutant W124Y
0.1
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
-
0.2
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
wild-type enzyme
0.4
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
mutant enzyme D112E
2
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
mutant enzyme W111R/D112E
3.8
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
fucosyltransferase III mutant enzyme D336A
0.5
Fucalpha(1,2)Galbeta(1,4)GlcNAc
-
mutant enzyme W111R/D112E
0.7
Fucalpha(1,2)Galbeta(1,4)GlcNAc
-
mutant enzyme W111R
0.7
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 7.0 and presence of Mn2+
0.9
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 4.7 and absence of Mn2+
1.5
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 4.7 and presence of Mn2+
3.3
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 7.0 and absence of Mn2+
0.6
Galbeta(1,3)GlcNAc
-
-
1.9
Galbeta(1,3)GlcNAc
-
-
12.7
Galbeta(1,3)GlcNAc
-
-
0.76
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
enzyme expressed n Sf9 cells
0.87
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
enzyme expressed in Trichoplusia ni
0.035
Galbeta(1,4)GlcNAc
-
-
1.6
Galbeta(1,4)GlcNAc
-
-
8.1
Galbeta(1,4)GlcNAc
-
-
0.35
Galbeta(1-3)GlcNAcbeta-O-Me
-
pH 6.5, 37°C, recombinant FucT VI
1.2
Galbeta(1-3)GlcNAcbeta-O-Me
-
pH 6.5, 37°C, recombinant FucT IV
0.03
GDP-fucose
mutant W124R, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.034
GDP-fucose
mutant W111Y, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.035
GDP-fucose
mutant W124Y, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.035
GDP-fucose
wildtype, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.037
GDP-fucose
mutant W111F, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.038
GDP-fucose
wildtype, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.046
GDP-fucose
mutant W111A, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.005
GDP-L-fucose
-
reaction with Galbeta(1,4)GlcNAc
0.0105
GDP-L-fucose
-
reaction with Galbeta(1,3)GlcNAc
0.013
GDP-L-fucose
FUT10-391
0.0131
GDP-L-fucose
-
reaction with lactose
0.015
GDP-L-fucose
FUT10-479
0.03
GDP-L-fucose
-
mutant enzyme W111R
0.032
GDP-L-fucose
-
mutant enzyme W111R/D112E
0.033
GDP-L-fucose
-
mutant enzyme D112E
0.0336
GDP-L-fucose
-
fucosyltransferase III
0.035
GDP-L-fucose
-
wild-type enzyme
0.15
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin
FUT10-479
0.154
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin
FUT10-391
3
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
25
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
1.1
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
11
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
0.61
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
16
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
0.4
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
5
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
0.67
NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn
-
enzyme form FTB
2.5
NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn
-
enzyme form FTA
0.1
NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
-
-
0.28
NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
-
-
0.77
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
-
enzyme form FTB
3.3
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
-
enzyme form FTB
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Wong, C.H.; Dumas, D.P.; Ichikawa, Y.; Koseki, K.; Danishefsky, S.J.; Weston, B.W.; Lowe, J.B.
Specificity, inhibition, and synthetic utility of a recombinant human alpha-1,3-fucosyltransferase
J. Am. Chem. Soc.
114
7321-7322
1992
Homo sapiens
-
brenda
Prieels, J.P.; Monnom, D.; Dolmans, M.; Beyer, T.A.; Hill, R.L.
Co-purification of the Lewis blood group N-acetylglucosaminide alpha 1-4 fucosyltransferase and an N-acetylglucosaminide alpha 1-3 fucosyltransferase from human milk
J. Biol. Chem.
256
10456-10463
1981
Homo sapiens
brenda
Palma, A.S.; Vila-Verde, C.; Pires, A.S.; Fevereiro, P.S.; Costa, J.
A novel plant alpha4-fucosyltransferase (Vaccinium myrtillus L.) synthesises the Lewisa adhesion determinant
FEBS Lett.
499
235-238
2001
Homo sapiens, Vaccinium myrtillus
brenda
Sousa, V.L.; Costa, M.T.; Palma, A.S.; Enguita, F.; Costa, J.
Localization, purification and specificity of the full-length membrane-bound form of human recombinant alpha 1,3/4-fucosyltransferase from BHK-21B cells
Biochem. J.
357
803-810
2001
Homo sapiens
brenda
Legault, D.J.; Kelly, R.J.; Natsuka, Y.; Lowe, J.B.
Human alpha(1,3/1,4)-fucosyltransferases discriminate between different oligosaccharide acceptor substrates through a discrete peptide fragment
J. Biol. Chem.
270
20987-20996
1995
Homo sapiens
brenda
Holmes, E.H.; Yen, T.Y.; Thomas, S.; Joshi, R.; Nguyen, A.; Long, T.; Gallet, F.; Maftah, A.; Julien, R.; Macher, B.A.
Human alpha1,3/4 fucosyltransferases. Characterization of highly conserved cysteine residues and N-linked glycosylation sites
J. Biol. Chem.
275
24237-24245
2000
Homo sapiens
brenda
Dupuy, F.; Germot, A.; Marenda, M.; Oriol, R.; Blancher, A.; Julien, R.; Maftah, A.
alpha1,4-Fucosyltransferase activity: a significant function in the primate lineage has appeared twice independently
Mol. Biol. Evol.
19
815-824
2002
Homo sapiens, Macaca mulatta
brenda
Morais, V.A.; Serpa, J.; Palma, A.S.; Costa, T.; Maranga, L.; Costa, J.
Expression and characterization of recombinant human alpha-3/4-fucosyltransferase III from Spodoptera frugiperda (Sf9) and Trichoplusia ni (Tn) cells using the baculovirus expression system
Biochem. J.
353
719-725
2001
Homo sapiens
brenda
Weston, B.W.; Nair, R.P.; Larsen, R.D.; Lowe, J.B.
Isolation of a novel human alpha (1,3)fucosyltransferase gene and molecular comparison to the human Lewis blood group alpha (1,3/1,4)fucosyltransferase gene. Syntenic, homologous, nonallelic genes encoding enzymes with distinct acceptor substrate specificities
J. Biol. Chem.
267
4152-4160
1992
Homo sapiens
brenda
Vo, L.; Lee, S.; Marcinko, M.C.; Holmes, E.H.; Macher, B.A.
Human alpha1,3/4-fucosyltransferases II. A single amino acid at the COOH terminus of FucT III and V alters their kinetic properties
J. Biol. Chem.
273
25250-25255
1998
Homo sapiens
brenda
Dupuy, F.; Petit, J.M.; Mollicone, R.; Oriol, R.; Julien, R.; Maftah, A.
A single amino acid in the hypervariable stem domain of vertebrate alpha1,3/1,4-fucosyltransferases determines the type 1/type 2 transfer. Characterization of acceptor substrate specificity of the Lewis enzyme by site-directed mutagenesis
J. Biol. Chem.
274
12257-12262
1999
Homo sapiens
brenda
Chandrasekaran, E.V.; Chawda, R.; Rhodes, J.M.; Xia, J.; Piskorz, C.; Matta, K.L.
Human lung adenocarcinoma alpha1,3/4-L-fucosyltransferase displays two molecular forms, high substrate affinity for clustered sialyl LacNAc type 1 units as well as mucin core 2 sialyl LacNAc type 2 unit and novel alpha1,2-L-fucosylating activity
Glycobiology
11
353-363
2001
Homo sapiens
brenda
Costa, J.; Grabenhorst, E.; Nimtz, M.; Conradt, H.S.
Stable expression of the Golgi form and secretory variants of human fucosyltransferase III from BHK-21 cells. Purification and characterization of an engineered truncated form from the culture medium
J. Biol. Chem.
272
11613-11621
1997
Homo sapiens
brenda
Kukowska-Latallo, J.F.; Larsen, R.D.; Nair, R.P.; Lowe, J.B.
A cloned human cDNA determines expression of mouse stage-specific embryonic antigen and the Lewis blood group alpha(1,3/1,4)fucosyltransferase
Genes Dev.
4
1288-1303
1990
Homo sapiens (P21217)
brenda
Cameron, H.S.; Szczepaniak, D.; Weston, B.W.
Expression of human chromosome 19p alpha(1,3)-fucosyltransferase genes in normal tissues. Alternative splicing, polyadenylation, and isoforms
J. Biol. Chem.
270
20112-20122
1995
Homo sapiens (P21217)
brenda
Elmgren, A.; Rydberg, L.; Larson, G.
Genotypic heterogeneity among Lewis negative individuals
Biochem. Biophys. Res. Commun.
196
515-520
1993
Homo sapiens (P21217)
brenda
Nishihara, S.; Yazawa, S.; Iwasaki, H.; Nakazato, M.; Kudo, T.; Ando, T.; Narimatsu, H.
alpha(1,3/1,4)fucosyltransferase (FucT-III) gene is inactivated by a single amino acid substitution in Lewis histo-blood type negative individuals
Biochem. Biophys. Res. Commun.
196
624-631
1993
Homo sapiens (P21217), Homo sapiens
brenda
Koda, Y.; Kimura, H.; Mekada, E.
Analysis of Lewis fucosyltransferase genes from the human gastric mucosa of Lewis-positive and -negative individuals
Blood
82
2915-2919
1993
Homo sapiens (P21217)
brenda
Mollicone, R.; Reguigne, I.; kelly, R.J.; Fletcher, A.; Watt, J.; Chatfield, S.; Aziz, A.; Cameron, H.S.; Weston, B.W.; Lowe, J.B.; Oriol, R.
Molecular basis for Lewis alpha(1,3/1,4)-fucosyltransferase gene deficiency (FUT3) found in Lewis-negative Indonesian pedigrees
J. Biol. Chem.
269
20987-20994
1994
Homo sapiens (P21217)
brenda
Nishihara, S.; Narimatsu, H.; Iwasaki, H.; Yazawa, S.; Akamatsu, S.; Ando, T.; Sena, T.; Narimatsu, I.
Molecular genetic analysis of the human Lewis histo-blood group system
J. Biol. Chem.
269
29271-29278
1994
Homo sapiens (P21217), Homo sapiens
brenda
Elmgren, A.; Boerjeson, C.; Svensson, L.; Rydberg, L.; Larson, G.
DNA sequencing and screening for point mutations in the human Lewis FUT gene enables molecular genotyping of the human Lewis blood group system
Vox Sang.
70
97-103
1996
Homo sapiens (P21217)
brenda
Elmgren, A.; Mollicone, R.; Costache, M.; Boerjeson, C.; Oriol, R.; Harrington, J.; Larson, G.
Significance of individual point mutations, T202C and C314T in the human Lewis FTA3' gene for expression of Lewis antigens by human alpha1,3/1,4'-fucosyltransferase, Fuc-TIII
J. Biol. Chem.
272
21994-21998
1997
Homo sapiens (P21217), Homo sapiens
brenda
Pang, H.; Liu, Y.; Koda, Y.; Soejima, M.; Jia, J.; Schlaphoff, T.; du Toit, E.D.; Kimura, H.
Five novel missense mutations of the Lewis gene FUT3' in African Xhosa and Caucasian populations in South Africa
Hum. Genet.
102
675-680
1998
Homo sapiens (P21217)
brenda
Koszdin, K.L.; Bowen, B.R.
The cloning and expression of a human alpha-1,3 fucosyltransferase capable of forming the E-selectin ligand
Biochem. Biophys. Res. Commun.
187
152-157
1992
Homo sapiens (P51993), Homo sapiens
brenda
Galan, M.C.; Venot, A.P.; Boons, G.J.
Glycosyltransferase activity can be modulated by small conformational changes of acceptor substrates
Biochemistry
42
8522-8529
2003
Homo sapiens
brenda
Niu, X.; Fan, X.; Sun, J.; Ting, P.; Narula, S.; Lundell, D.
Inhibition of fucosyltransferase VII by gallic acid and its derivatives
Arch. Biochem. Biophys.
425
51-57
2004
Homo sapiens (Q11130)
brenda
Stoykova, L.I.; Liu, A.; Scanlin, T.F.; Glick, M.C.
alpha1,3 Fucosyltransferases in cystic fibrosis airway epithelial cells
Biochimie
85
363-367
2003
Homo sapiens
brenda
Palma, A.S.; Morais, V.A.; Coelho, A.V.; Costa, J.
Effect of the manganese ion on human alpha3/4 fucosyltransferase III activity
BioMetals
17
35-43
2004
Homo sapiens
brenda
Norris, A.J.; Whitelegge, J.P.; Strouse, M.J.; Faull, K.F.; Toyokuni, T.
Inhibition kinetics of carba- and C-fucosyl analogues of GDP-fucose against fucosyltransferase V: implication for the reaction mechanism
Bioorg. Med. Chem. Lett.
14
571-573
2004
Homo sapiens
brenda
Chandrasekaran, E.V.; Chawda, R.; Rhodes, J.M.; Locke, R.D.; Piskorz, C.F.; Matta, K.L.
The binding characteristics and utilization of Aleuria aurantia, Lens culinaris and few other lectins in the elucidation of fucosyltransferase activities resembling cloned FT VI and apparently unique to colon cancer cells
Carbohydr. Res.
338
887-901
2003
Homo sapiens (P51993), Homo sapiens (Q11128)
brenda
Abe, H.; Ohba, M.; Shimma, Y.I.; Jigami, Y.
Yeast cells harboring human alpha-1,3-fucosyltransferase at the cell surface engineered using Pir, a cell wall-anchored protein
FEMS Yeast Res.
4
417-425
2004
Homo sapiens
brenda
Dupuy, F.; Germot, A.; Julien, R.; Maftah, A.
Structure/function study of Lewis alpha3- and alpha3/4-fucosyltransferases: the alpha1,4 fucosylation requires an aromatic residue in the acceptor-binding domain
Glycobiology
14
347-356
2004
Homo sapiens (P21217), Homo sapiens (P51993), Homo sapiens (Q11128), Hylobates lar (Q8HYJ3), Pongo pygmaeus (Q8HYJ4), Pongo pygmaeus (Q8HYJ5), Gorilla gorilla (Q8HYJ6), Gorilla gorilla (Q8HYJ7)
brenda
Morais, V.A.; Costa, J.
Stable expression of recombinant human alpha3/4 fucosyltransferase III in Spodoptera frugiperda Sf9 cells
J. Biotechnol.
106
69-75
2003
Homo sapiens
brenda
Guo, P.; Zhang, Y.; Zhang, X.Y.; Chen, H.L.; Wang, H.; Narimatsu, H.
Analysis of lewis antigens on cell surface and alpha1,3 fucosyltransferase subtypes in H7721 human hepatocarcinoma cells
J. Exp. Clin. Cancer Res.
22
135-139
2003
Homo sapiens
brenda
Bengtson, P.; Lundblad, A.; Larson, G.; Pahlsson, P.
Polymorphonuclear leukocytes from individuals carrying the G329A mutation in the alpha 1,3-fucosyltransferase VII gene (FUT7) roll on E- and P-selectins
J. Immunol.
169
3940-3946
2002
Homo sapiens
brenda
Dabrowska, A.; Baczynska, D.; Widerak, K.; Laskowska, A.; Ugorski, M.
Promoter analysis of the human alpha1,3/4-fucosyltransferase gene (FUT III)
Biochim. Biophys. Acta
1731
66-73
2005
Homo sapiens
brenda
Escrevente, C.; Machado, E.; Brito, C.; Reis, C.A.; Stoeck, A.; Runz, S.; Marme, A.; Altevogt, P.; Costa, J.
Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines
Int. J. Oncol.
29
557-566
2006
Homo sapiens
brenda
Khaled, A.; Piotrowska, O.; Dominiak, K.; Auge, C.
Exploring specificity of glycosyltransferases: synthesis of new sugar nucleotide related molecules as putative donor substrates
Carbohydr. Res.
343
167-178
2008
Homo sapiens
brenda
Shetterly, S.; Jost, F.; Watson, S.R.; Knegtel, R.; Macher, B.A.; Holmes, E.H.
Site-specific fucosylation of sialylated polylactosamines by alpha1,3/4-fucosyltransferases-V and -VI is defined by amino acids near the N terminus of the catalytic domain
J. Biol. Chem.
282
24882-24892
2007
Homo sapiens
brenda
Lin, C.H.; Lin, C.W.; Khoo, K.H.
Proteomic identification of specific glycosyltransferases functionally implicated for the biosynthesis of a targeted glyco-epitope
Proteomics
8
475-483
2008
Homo sapiens (P21217), Homo sapiens (P51993)
brenda
Tefsen, B.; van Stijn, C.M.; van den Broek, M.; Kalay, H.; Knol, J.C.; Jimenez, C.R.; van Die, I.
Chemoenzymatic synthesis of multivalent neoglycoconjugates carrying the helminth glycan antigen LDNF
Carbohydr. Res.
344
1501-1507
2009
Homo sapiens
brenda
Fagerberg, D.; Angstroem, J.; Halim, A.; Hultberg, A.; Rakhimova, L.; Hammarstroem, L.; Boren, T.; Teneberg, S.
Novel Leb-like Helicobacter pylori-binding glycosphingolipid created by the expression of human alpha-1,3/4-fucosyltransferase in FVB/N mouse stomach
Glycobiology
19
182-191
2009
Homo sapiens
brenda
Carvalho, A.; Harduin-Lepers, A.; Magalhaes, A.; Machado, E.; Mendes, N.; Costa, L.; Matthiesen, R.; Almeida, R.; Costa, J.; Reis, C.
Differential expression of alpha-2,3-sialyltransferases and alpha-1,3/4-fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells
Int. J. Biochem. Cell Biol.
42
80-89
2010
Homo sapiens
brenda
Mollicone, R.; Moore, S.E.; Bovin, N.; Garcia-Rosasco, M.; Candelier, J.J.; Martinez-Duncker, I.; Oriol, R.
Activity, splice variants, conserved peptide motifs, and phylogeny of two new alpha1,3-fucosyltransferase families (FUT10 and FUT11)
J. Biol. Chem.
284
4723-4738
2009
Homo sapiens (Q495W5), Homo sapiens (Q6P4F1)
brenda
Barthel, S.; Wiese, G.; Cho, J.; Opperman, M.; Hays, D.; Siddiqui, J.; Pienta, K.; Furie, B.; Dimitroff, C.
Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking
Proc. Natl. Acad. Sci. USA
106
19491-19496
2009
Homo sapiens
brenda
Guo, Q.; Guo, B.; Wang, Y.; Wu, J.; Jiang, W.; Zhao, S.; Qiao, S.; Wu, Y.
Functional analysis of alpha1,3/4-fucosyltransferase VI in human hepatocellular carcinoma cells
Biochem. Biophys. Res. Commun.
417
311-317
2012
Homo sapiens
brenda
Seelhorst, K.; Piernitzki, T.; Lunau, N.; Meier, C.; Hahn, U.
Synthesis and analysis of potential alpha1,3-fucosyltransferase inhibitors
Bioorg. Med. Chem.
22
6430-6437
2014
Helicobacter pylori, Homo sapiens
brenda
Lunau, N.; Seelhorst, K.; Kahl, S.; Tscherch, K.; Stacke, C.; Rohn, S.; Thiem, J.; Hahn, U.; Meier, C.
Fluorescently labeled substrates for monitoring alpha1,3-fucosyltransferase IX activity
Chemistry
19
17379-17390
2013
Helicobacter pylori, Homo sapiens
brenda
Brazil, J.C.; Liu, R.; Sumagin, R.; Kolegraff, K.N.; Nusrat, A.; Cummings, R.D.; Parkos, C.A.; Louis, N.A.
alpha3/4 Fucosyltransferase 3-dependent synthesis of Sialyl Lewis A on CD44 variant containing exon 6 mediates polymorphonuclear leukocyte detachment from intestinal epithelium during transepithelial migration
J. Immunol.
191
4804-4817
2013
Homo sapiens
brenda
Huang, V.W.; Lee, C.L.; Lee, Y.L.; Lam, K.K.; Ko, J.K.; Yeung, W.S.; Ho, P.C.; Chiu, P.C.
Sperm fucosyltransferase-5 mediates spermatozoa-oviductal epithelial cell interaction to protect human spermatozoa from oxidative damage
Mol. Hum. Reprod.
21
516-526
2015
Homo sapiens
brenda